Last updated: 11/04/2018 09:52:30
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
GSK study ID
NOS102512
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of doses of 5-180 mg of the iNOS inhibitor GW274150 in the Treatment of Acute Migraine during the Mild Headache Phase
Trial description: Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the acute treatment of migraine headache.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Drug: GW274150
Enrollment:
126
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Migraine Disorders
Product
GW274150
Collaborators
Not applicable
Study date(s)
December 2005 to August 2006
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Suffering from migraine with or without aura.
- Migraine for at least one year, and the age of onset was prior to 50 years.
- As a result of the medical interview, physical examination or screening investigations, that the doctor considers the subject unfit for the study.
- History of alcohol, substance or drug abuse within the last year.
Inclusion and exclusion criteria
Inclusion criteria:
- Suffering from migraine with or without aura.
- Migraine for at least one year, and the age of onset was prior to 50 years.
- Consistent migraine headache over time and has had at least 1 migraine headache attacks but less than 15 days with headache (migraine or non-migraine) per month in each of the three months prior to the Screening Visit and maintains this requirement during the baseline period.
- Able to distinguish migraine headache attacks as discreet attacks from other headaches (i.e. tension-type headaches).
- Typically have moderate to severe migraine pain preceded by an identifiable mild pain phase.
- No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the doctor considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
- Written informed consent prior to entry into the study.
- Females who are: a) non-childbearing potential or, b) of child-bearing potential, has a negative pregnancy test at screen, and is taken adequate contraceptive measures.
Exclusion criteria:
- As a result of the medical interview, physical examination or screening investigations, that the doctor considers the subject unfit for the study.
- History of alcohol, substance or drug abuse within the last year.
- Taken a migraine prophylactic medication within 1 month of the Screening Visit.
- Uses an opiate as first line acute treatment for migraine attacks.
- History of ergotamine, triptan, opioid, or combination medication intake on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months.
- History of simple analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months.
- Do not receive migraine relief from a triptan migraine treatment.
- Uncontrolled hypertension at the Screening Visit, defined as systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg.
- Evidence of renal impairment
- calculated creatinine clearance <60ml/min or clinically relevant finding on urinalysis.
- History of drug or other allergy which, in the opinion of the doctor, makes the subject unsuitable for participation in the study.
Trial location(s)
Location
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Status
Study Complete
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2006-01-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website